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Abstract 
Background:  People with depression tend to have lower heart rate variability (HRV), but the 
temporal sequence is poorly understood. In a sample of the general population, we 
prospectively examined whether HRV measures predict subsequent depressive symptoms or 
whether depressive symptoms predict subsequent levels of HRV. 
Method: Data from the fifth (1997-1999) and ninth (2007-2009) phases of the UK Whitehall 
II longitudinal population-based cohort study were analysed with an average follow-up of 
10.5 years. The sample size for the prospective analysis depended on the analysis and ranged 
from 2334 (644 women) to 2276 (602 women). HRV measures during 5 minutes of supine 
rest were obtained. Depressive symptoms were evaluated by 4 cognitive symptoms of 
depression from the General Health Questionnaire.  
Results: At follow-up assessment, depressive symptoms were inversely associated with HRV 
measures independently of antidepressant medication use in men but not in women.  
Prospectively, higher baseline heart rate and higher HRV measures were associated with a 
lower likelihood of incident depressive symptoms at follow-up in men without depressive 
symptoms at baseline. Similar but statistically insignificant associations were found in 
women. Adjustments for known confounders including socio-demographic and lifestyle 
factors, cardio-metabolic conditions or medication did not change the predictive effect of 
HRV on incident depressive symptoms at follow-up. Depressive symptoms at baseline were 
not associated with heart rate or HRV at follow-up in either sex.  
Conclusions: These findings are consistent with an etiologic role of the autonomic nervous 
system in the depression onset.  
 
Keywords: depressive symptoms, autonomic, heart rate variability, longitudinal cohort study, 
etiological significance 
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Introduction 
 
Epidemiological and clinical research suggests that depression is associated with a host of 
cardiovascular conditions (Hare et al. 2014). Depression is common in cardiac patients, while 
depressive symptoms also predict future cardiovascular disease (CVD) (Nicholson et al. 
2006; Hare et al. 2014). A variety of  mechanisms underlying this association have been 
postulated (Grippo & Johnson 2009; Nemeroff & Goldschmidt-Clermont 2012).  
Disturbed autonomic nervous system (ANS), including decreased parasympathetic 
and/or increased sympathetic tone, may be one pathway linking depression and negative 
cardiac outcomes (Stapelberg et al. 2012). Heart rate variability (HRV) is non-invasive 
technique estimating the ANS characteristics (Task Force 1996). Low HRV indicative of 
diminished vagal cardiovascular modulations is a known predictor of cardiac morbidity and 
mortality, and an indicator of stress vulnerability and low capacity for parasympathetic 
inhibition of autonomic arousal in emotional regulation (Task Force 1996; Thayer et al. 
2012).  
A number of epidemiological and clinical studies have shown depression to be 
associated with unfavourable HRV indices, notably reduced cardiac vagal modulation 
(Rottenberg 2007; Licht et al. 2008, 2010; Kemp et al. 2010; Dauphinot et al. 2012; Brunoni 
et al. 2013). For example, a meta-analysis of clinical studies demonstrated that relative to 
controls, physically healthy un-medicated patients with major depressive disorder displayed 
reduced vagal HRV indices (Kemp et al. 2010). In a more recent double-blind, randomized, 
placebo-controlled trial, moderately to severely depressed un-medicated patients with low 
cardiovascular risk profile had lower HRV compared to controls (Brunoni et al. 2013). There 
is epidemiological evidence that the depression/HRV relationship is partly or fully driven by 
use of antidepressants (Licht et al. 2008, 2010; Kemp et al. 2014; O’Regan et al. 2014). 
4 
 
However, this does not apply to un-medicated participants (Kemp et al. 2010; Brunoni et al. 
2013).  
Although the association between HRV and depression has been studied extensively, 
the directionality of the HRV-depression relationship received less attention. Possible 
mechanisms exist for a bidirectional relationship. On the one hand, chronic exposure to 
stressful experiences and prolonged negative emotions have been shown to lead to increased 
sympathetic and reduced parasympathetic modulation (Grippo & Johnson 2009) suggesting 
that depression may precede low HRV. On the other hand, other evidence supports the 
possibility that low HRV precedes depression. Namely, (1) reduced modulation of vagal 
activity and HRV leads to a variety of conditions associated with increased allostasis and poor 
health (Thayer & Sternberg 2006); (2) vagal stimulation, associated with HRV increase 
(Zhang et al. 2009) improves mood and reduces depressive symptoms severity both in 
humans and animals (Vonck et al. 2014); (3) rats with complete disconnection of abdominal 
vagal afferents displayed reduced innate negative emotional behaviour compared to controls 
(Klarer et al. 2014); and (4) reduced vagal HRV indices has been shown to predict a more 
pernicious course of depression (Chambers & Allen 2002; de Guevara et al. 2004). 
Rottenberg (2007) has argued that prospective study designs should be used to test the 
potential etiological role of the ANS in depression in individuals with no history of 
depression. 
The Whitehall II study is a large longitudinal population-based cohort study in which 
short-term HRV and cognitive symptoms of depression were measured repeatedly over a 10 
year interval. This has enabled us to prospectively examine whether decreased HRV predicts 
subsequent incident depressive symptoms in non-depressed individuals, and whether 
depressive symptoms predict subsequent HRV reductions. Additionally, we also evaluated to 
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what extent potential longitudinal associations were influenced by covariates including 
sociodemographic and lifestyle factors, cardio-metabolic condition and medication use.  
 
Methods  
Study population 
The Whitehall II study is an ongoing cohort study of subjects initially employed by the British 
civil service originally set up to explore the degree and causes of the social gradient in 
morbidity and mortality.  The target population was all London-based office staff, aged 35–55 
years. A total of 10,308 subjects (3,413 women, response rate of 73%), were initially recruited 
between 1985 and 1988 (Marmot & Brunner 2005). After the baseline examination, follow-up 
medical examinations have taken place approximately every 5 years. HRV recordings were 
made at the fifth (1997-1999), seventh (2002-2004) and ninth (2007-2009) data collection 
phases. The University College London ethics committee approved the study and participants 
gave informed consent. Whitehall II data, protocols, and other metadata are available to bona 
fide researchers for research purposes (data sharing policy is available at 
http://www.ucl.ac.uk/whitehallII/data-sharing). 
The present study included participants with data on cognitive symptoms of depression 
and HRV at phase 5 (1997-1999) or phase 9 (2007–2009). Mean follow-up was 10.5 years 
(range 8.9 – 12.3). Phase 5 is used as the baseline and phase 9 as the follow-up. The number 
of participants who had data on cognitive symptoms of depression and HRV was 949 women 
and 2268 men at baseline, and 1293 women and 3451 men at follow-up. The sample size for 
the prospective analysis ranged from 2334 (644 women) to 2276 (602 women) dependent on 
the completeness of covariate data.  
 
HRV measurements  
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Details on the assessment of heart rate and HRV in Whitehall II can be found elsewhere 
(Hemingway et al. 2005; Britton et al. 2007). Briefly, five minute supine resting 12-lead 
electrocardiograms (ECG) were obtained after 5 min of rest. At phases 5 and 9, KardiosisTM 
ECG acquisition module (Tepa, Inc., Turkey) and Getemed ECG recorder (Getemed Teltow, 
Germany) were used, respectively. The sampling frequencies and outputs of the different 
devices were comparable. Using an automatic algorithm (Acar et al. 2000), normal sinus-
rhythm QRS complexes suited for a reliable HRV analysis were identified. Although in short-
term recordings obtained at standardized conditions, spectral HRV analysis is the preferred 
method (Task Force 1996), in this study HRV was analysed in both time- and frequency-
domain. Time-domain measures included the standard deviation (SD) of all normal-to-normal 
RR intervals (SDNN) and root mean square of successive differences of normal-to-normal RR 
intervals (RMSSD). Frequency-domain components were computed using a Blackman-Tukey 
algorithm. The low frequency (LF-HRV), 0.04 to 0.15 Hz, and high frequency (HF-HRV), 
0.15 to 0.4 Hz, spectral power was obtained. The RMSSD and HF-HRV reflect 
parasympathetic modulation. The interpretation of LF-HRV is controversial but most 
evidence suggest that it reflects both parasympathetic and sympathetic modulations. Under 
particular circumstances, it may be influenced by different regulatory mechanisms including, 
among others,  respiration  and baroreflex control (Task Force 1996; Bernardi et al. 2000; 
Lahiri et al. 2008; Goldstein et al. 2011; Reyes del Paso et al. 2013). 
 
Depressive symptoms 
Symptoms of depression were measured using a 4-item scale derived from the 30-item 
General Health Questionnaire (GHQ) (Goldberg & Hillier 1979). The General Health 
Questionnaire is used to detect minor psychiatric disorders including depressive disorder, 
suitable for use in general population samples (GHQ) (Goldberg 1972). The 30-item GHQ 
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was validated within the Whitehall II Study (Stansfeld et al. 1998) based on principal 
components factor analysis and a comparison with the 7-item severe depression subscale from 
the 28-item GHQ. The depression symptom score includes the following four items: “been 
thinking of yourself as a worthless”, “felt that life is entirely hopeless”, “felt that life isn´t 
worth living”, and “found at times you couldn´t do anything because your nerves were too 
bad” (Cronbach´s α = 0.88). Responses to these items were on a four-point Likert scale (0 = 
“not at all”, 1 = “no more than usual”, 2 = “rather more than usual”, and 3 = “much more than 
usual”) giving a range of 0 to 12. A sum score was calculated and, as previously, a total score 
of 4 or more was used to define cognitively based symptoms of depression (Stansfeld et al. 
1998). The test-retest reliability was r = 0.78 in a sub-sample of 286 participants who repeated 
the GHQ within 1 month (Stansfeld et al. 2003). The respondents were considered as having a 
depressive episode if they scored  ≥ 4 on the GHQ depression subscale or reported the use of 
prescribed antidepressant medication (Stansfeld et al. 2003). 
 
Covariates 
Relevant confounders that have been previously shown to be associated with HRV and 
depression (Huikuri et al. 1998; Rennie et al. 2003; Hemingway et al. 2005; Marmot & 
Brunner 2005; Schroeder et al. 2005; Britton et al. 2007) were included as covariates and 
were obtained from phase 5 unless otherwise stated. Socio-demographic characteristics 
included age (mean), ethnicity (white vs. other) and civil service employment grade. Lifestyle 
factors included leisure-time physical activity, alcohol consumption and smoking habits, and 
were assessed by self-completed questionnaires. Participants were asked how often they took 
part in moderate and vigorous exercise such as walking, cycling, sports, gardening, 
housework, and home maintenance. Those participants undertaking less than 1hour per week 
of vigorous physical activity or less than 2.5 hours per week of moderate physical activity did 
not meet WHO recommendations (2010) and were defined as exercising little or none (Sabia 
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et al. 2009). Alcohol consumption in the past week was expressed in units of alcohol (1 U = 8 
g), and ≥14 U/week in women and ≥21 U/week in men were categorized as high 
consumption. Smoking habits were categorized as non/ex/current smoker. Cardio-metabolic 
conditions were assessed as the presence of any of the following chronic diseases or health-
related conditions: diagnosed CHD including heart failure, stroke, diabetes, hypertension (use 
of hypertensive medication or blood pressure ≥140/90 mmHg) and obesity (body mass index, 
BMI ≥ 30 kg/m2). Blood pressure and BMI were assessed according to standard guidelines. 
Medication use included any prescribed medication within last 14 days. Antidepressant 
medication use both at phase 5 and 9 was recorded separately as previous studies have shown 
antidepressant treatment to influence the HRV-depression association (Licht et al. 2008, 
2010; O’Regan et al. 2014).  
 
Statistical analysis 
Linear and logistic regressions were used to explore cross-sectional and prospective 
associations between HRV and depression symptoms. Heart rate and HRV measures were 
used as continuous variables. Depressive symptoms were used as a continuous and categorical 
variable for cross-sectional and prospective analyses, respectively. Models were adjusted for 
age and ethnicity since they are known to influence HRV (Task Force 1996; Hemingway et 
al. 2005; Britton et al. 2007). Results are presented as odds ratios (OR) or unstandardized 
regression coefficients (β) with 95% confidence intervals (CIs). The level of statistical 
significance was set at p ≤ 0.05. Intentionally, we have not corrected the p-values for multiple 
comparisons (Rothman 1990, 2014; Saville 1990). HRV values were logarithmically 
transformed prior to analyses to handle their skewed distributions. Depression score was also 
skewed but none of the transformations (log,  square-root, cubic, square, inverse and  others) 
provided normal distribution of data so results are presented in terms of raw depression 
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scores, for ease of interpretation. The results of both cross-sectional and prospective analyses 
were virtually unchanged when depression score was log or square-root transformed (data not 
shown). 
Cross-sectional analyses, undertaken among participants with no antidepressant 
medication use were assessed by linear regression both at phase 5 and phase 9. The first 
prospective model, using binary logistic regression, examined whether HRV at phase 5 (1997-
1999) was associated with incident depressive symptoms at phase 9 (2007-2009), while 
adjusting for depressive symptoms score at phase 5 (1997-1999). This analysis focused on 
participants without a depression at phase 5 baseline, i.e. participants with GHQ score ≥ 4 or 
those reporting antidepressant medication use at phase 4 (1995-1996) and 5 (1997-1999) were 
excluded. Cases of incident depressive symptoms at follow-up were defined as participants 
having GHQ score ≥ 4 or reporting use of antidepressant medication at phase 9 (2007-2009). 
In the second prospective model, linear regression explored the association between 
depressive symptoms at phase 5 (1997-1999) and HRV measures at phase 9 (2007-2009), 
while adjusting for HRV at phase 5 (1997-1999). Cases of incident depressive symptoms at 
baseline (phase 5) were defined as participants having GHQ score ≥ 4 or reporting 
antidepressant medication use at phase 5.  
Analyses were not constrained to participants with complete data on HRV measures and 
cognitive symptoms of depression at both phases. To ensure that sample differences did not 
account for differences in results, models were repeated using the same sample for all 
analyses. This had little effect on the pattern of associations, so results are presented using all 
the available data for each analysis. 
In order to assess the predictive ability of HRV measures we used receiver operator 
characteristic (ROC) analysis to generate area under the ROC curve (AUC). The ROC curves 
plot the positive fraction, or sensitivity against the false positive fraction (1-specificity) by 
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varying the threshold value for the test. The ROC curve indicates the probability of a true 
positive result as a function of the probability of a false positive result for all possible 
threshold values. The AUC is a quantitative measure of selectivity: 0.5 indicates that the test 
results are no better than those obtained by chance, whereas an area of 1.0 indicates a 
perfectly sensitive and specific test. The contribution of the covariates to the association 
between HRV and symptoms of depression was explored in logistic regression models. To the 
basic model adjusted for age, sex and ethnicity each of the following sets of factors were 
individually included: employment grade, lifestyle factors, cardio-metabolic condition and 
medication use. Subsequently, a model adjusted for all covariates was used. All analyses were 
computed in STATA (version 12; StataCorp LP, College Station, TX, USA).  
 
Results 
Of the 10,308 participants at phase 1 (1985-1988), 306 died before the start of HRV data 
collection at phase 5 (1997-1999). Table 1 presents the descriptive characteristics of 
participants with data on both depressive symptoms and HRV either at phase 5 baseline or 
phase 9 follow-up. At both phases, there were more males (70.5% and 72.6%) and the 
majority of participants were of white origin. Average levels of depressive symptoms and 
heart rate, RMSSD and HF-HRV were higher (p ≤ 0.005) and LF-HRV lower (p ≤ 0.001) in 
women than in men. Women included a higher proportion of participants from ethnic 
minorities and were more likely to be from the lower employment grades. On average, twice 
as many women than men were taking antidepressant medication. Compared with phase 5, at 
phase 9 there was about one third higher proportion of women and men taking antidepressant 
medication and consequently lower average levels of depressive symptoms.   
 
Insert Table 1 here 
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Table 2 shows the cross-sectional associations between HRV measures (but not HR and 
RMSSD) and depressive symptoms at baseline (phase 5) and follow-up (phase 9) in 
participants not using antidepressant medication. In these subjects, depressive symptoms 
score was not significantly associated with heart rate or HRV at baseline. In the cross-
sectional analyses at follow-up, higher depressive symptoms score was significantly 
associated with lower SDNN (β = -0.01; p = 0.04), LF-HRV (β = -0.03; p = 0.02) and HF-
HRV (β = -0.04; p = 0.04) among men, but not among women. At both phases, there were no 
significant associations between depressive symptoms score and HR or RMSSD in both 
sexes. 
 
Insert Table 2 here 
 
Table 3 and Figure 1 present the results from the prospective logistic analysis estimating 
associations between HRV at baseline (phase 5) and depressive symptoms at follow-up (phase 
9). Results indicated that among men without a depressive episode at phase 4 (1995-1996) 
and 5 (1997-1999), HRV at baseline (phase 5) predicted incident depressive symptoms at 
follow-up (phase 9). Specifically, lower heart rate and higher SDNN, RMSSD, LF-HRV and 
HF-HRV were associated with lower likelihood of depressive symptoms (Heart rate: OR = 
1.02, 95% CI. 1.01-104, p = 0.011; SDNN: OR = 0.57, 95% CI. 0.36-0.89, p = 0.013; 
RMSSD: OR = 0.65, 95% CI. 0.46-0.92, p = 0.016; LF-HRV: OR = 0.77, 95% CI. 0.63-0.94, 
p = 0.010; HF-HRV: OR = 0.81, 95% CI. 0.67-0.98, p = 0.031). For example, for men, the 
odds of elevated depressive symptoms or antidepressant medication use at follow-up 
decreased by 35% for every unit increase in log-transformed RMSSD or by 19% for every 
unit increase in log-transformed HF-HRV. Age-adjusted arithmetic- and geometric-means of 
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HR and HRV measures at phase 5 for those men who developed depressive symptoms at 
follow-up (n=106) compared to those who did not (n=1584) are as follows: for HR 71.7 bpm 
vs. 68.4 bpm; for SDNN 30.9ms2 vs 34.8ms2; for LF-HRV 259.5ms2 vs. 338.1ms2; for HF-
HRV 95.6ms2 vs. 121ms2; for RMSSD 17.1ms2 vs. 20ms2. The receiver operator curve 
analysis yielded AUC of 0.72 (95% CI. 0.67-0.78) for SDNN and 0.73 (95% CI. 0.67-0.79) 
for HR, LF-HRV, HF-HRV and RMSSD.   For women, the predictive effect of heart rate or 
HRV in incident depressive symptoms did not reach the statistically significant level (p ≥ 
0.062), although the HRV associations were similar to those in men (AUC: 0.67-0.69, 95% 
CI. 0.60-0.76).   
 
Insert Table 3 here 
 
Table 4 presents the results from the adjusted prospective logistic analyses assessing the 
contribution of the five sets of covariates to the association between HRV at baseline and 
cognitive symptoms of depression at follow-up in men. None of the covariates, individually or 
in combination, accounted for more than a relatively small part of the association (4.95% for 
SDNN, 1.95% for HF-HRV and 3.76% RMSSD in combination of all covariates). In women, 
covariate adjustment did not alter the non-significant association between HRV at baseline 
and depressive symptoms at follow-up (data not shown).   
 
Insert Table 4 here 
 
The examination of cognitive symptoms of depression at baseline (phase 5) as predictors of 
heart rate and HRV measures at follow-up (phase 9) did not reveal any significant association 
in either sex (p > 0. 348) (data not shown). 
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Discussion 
 
Based on a large community sample, our investigation suggests that cognitive symptoms of 
depression are associated with HRV independently of antidepressant medication use, in both 
cross-sectional and longitudinal associations. Over a 10-years period, we found that in 
individuals without depressive symptoms, lower heart rate and higher SDNN, RMSSD, LF-
HRV and HF-HRV predicted subsequent incident depressive symptoms. This association was 
independent of socio-demographic and lifestyle factors, cardio-metabolic condition and/or 
medication use and baseline cognitive symptoms of depression. Depressive symptoms did not 
predict subsequent levels of heart rate or HRV. Results suggest that disturbances of cardiac 
autonomic status, particularly low vagal modulation, precede depressive symptoms.  
The findings in the cross-sectional analyses at phase 9 are consistent with previous 
clinical and epidemiological studies showing an inverse association of HRV with depressive 
symptoms or major depressive disorder independently of antidepressant treatment (Kemp et 
al. 2010; Dauphinot et al. 2012; Brunoni et al. 2013).  Although the significant cross-
sectional association was observed only at phase 9, the cross-sectional effect is nevertheless 
present, suggesting that antidepressant use does not fully drive the relationship between HRV 
and depression as some authors report in other studies (Licht et al. 2008, 2010; Kemp et al. 
2014; O’Regan et al. 2014). We believe that the cross-sectional association at phase 5 was not 
significant due to smaller sample size at phase 5 compared with phase 9. As seen in the Table 
2, regression coefficients for some HRV measures (e.g. SDNN and LF-HRV in men) did not 
change much from phase 5 to phase 9, but they were significant in phase 9 only.  In order to 
further explore the cross-sectional association between HRV and depressive symptoms we 
conducted an analysis using data from phase 7. Results indicated similar size of the regression 
coefficients between depressive symptoms and HRV measures and significant associations in 
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men (data not shown). This supports the presence of the overall cross-sectional association 
between HRV and depressive symptoms independently of antidepressant treatment. 
A number of previous studies have tested whether lower vagal HRV indices among 
depressed individuals predict a more pernicious course of disorder (Chambers & Allen 2002; 
de Guevara et al. 2004). To our knowledge, the predictive effect of HRV on incident 
depression in a large sample of general population without depressive symptoms at baseline 
has not been investigated before. The cognitive symptoms of depression can be regarded as a 
part of the prodromal phase of major depressive disorder and therefore can be considered as a 
significant risk indicator of major depressive disorder (Cuijpers & Smit 2004). Our results 
suggest that low HRV and vagal modulation, as reflected by decreased RMSSD and HF-
HRV, play an etiologic role in incident depression rather than contributing to the later stages 
of depression development among men. As seen in Table 3 the odds of depressive symptoms 
at follow-up decreased by 43% for every unit increase in log-transformed SDNN and by 35% 
and 19% for every unit increase in log-transformed RMSSD and HF-HRV. Additionally, 
ROC analysis revealed a high sensitivity and specificity (0.72-0.73) of HR and HRV 
measures for the prediction of incidence cognitive symptoms of depression in men. Findings 
indicate that the contribution of ANS disturbance to depressive symptoms is quite large.  
The findings on the predictive effect of HRV in depression generation in men accords 
with the study by Gimeno et al. (2009). Over a period of 12 years within Whitehall II 
population, inflammatory markers were shown to precede subsequent cognitive symptoms of 
depression while depressive symptoms did not precede subsequent average levels of 
inflammatory markers (Gimeno et al. 2009). As the ANS plays a homeostatic role in relation 
to the inflammatory response (Tracey 2002), and lower HRV has been shown to predict 
inflammation (Jarczok et al. 2014), our results are complementary to earlier work (Gimeno et 
al. 2009). The predictive effects of HRV, and inflammation respectively, on future depressive 
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symptoms were independent of potential covariates and stronger in men than in women. A 
possible alternative interpretation accounting for the lack of predictive association between 
depressive symptoms and subsequent physiological functioning (as indexed by average levels 
of HRV) in our study, may be the long period of follow-up and narrow scope of the 
depression measure. Assessment of neuro-vegetative symptoms, which might more readily be 
expected to be associated with physiological disturbances, may have produced stronger cross-
sectional association and potentially evidence of bidirectional association between HRV and 
depression.  
Our findings of etiological significance of HRV in depression generation is in agreement with 
polyvagal theory and neuro-visceral integration model (Porges 1995; Thayer & Lane 2000). 
According to these theories the affective and social behaviour in mammals is dependent on 
the ability to regulate visceral homeostasis, including control of heart, mediated by vagal 
signalling (Porges 1995; Rottenberg 2007; Thayer et al. 2012). Findings of neuroimaging 
studies (Thayer et al. 2012), have indeed shown low HRV and vagal modulation to be 
associated with number of brain regions, including prefrontal cortex and amygdala, that are 
involved in emotional dysregulation. Insufficient vagal functioning, may therefore have a 
direct impact on emotion and social communication, which can in turn manifest as cognitive 
symptoms of depression or major depressive disorder (Rottenberg 2007). Therefore the well-
known association between depressive symptoms and cardiac health may be due in part to 
disturbed ANS and low vagal modulation, rather than depression per se. Based on results of 
our and previous studies, low HRV and vagal modulation may be risk factors for both 
depression and CHD. Vagal pathways could therefore be intervention targets. For instance, it 
has been shown that enhancing vagal cardiac modulation by physical activity or vagal 
stimulation, have favorable effects on HRV, emotions or cardiac health (Soares-Miranda et al. 
2014; Vonck et al. 2014). 
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It is unclear why the prospective association was significant only among men and not 
among women even though it was in the expected direction. As the number of men was nearly 
three times larger than of women, it may be possible that increasing a sample size in women 
would lead to narrower confidence intervals and probably to significant HRV-depression 
association. Another possible explanation is that  differences in the neural control of the heart 
and in achieving homeostasis may have impacted our observations (Smetana & Malik 2013). 
On average women have reduced sympathetic and increased parasympathetic modulation of 
heart rate relative to men as well as different biological ways of responding to stress (Hassan 
et al. 2008). Furthermore depression has been shown to manifest differently in men and 
women; relative to men, women show more somatic symptoms of depression (Silverstein et 
al. 2013). It is possible that we were not able to detect depression in some women due the 
scale used to assess depression.  
In our data the associations between HRV and depressive symptoms were not explained 
by potential covariates. By adjusting for cardio-metabolic condition (the presence of 
diagnosed CHD, stroke, diabetes, hypertension and/or obesity) we were able to control for the 
possibility that our observed associations were due to confounding by physical illness and 
pre-existing illness at baseline. These adjustments explained a maximum of 1.5% of the HRV-
depression association. Similarly medication use within last 2 weeks as well as lifestyle 
factors and SES had little effect on the association. After simultaneous adjustments for all 
mentioned covariates the association remained virtually unchanged (explained a maximum of 
2% of the association).  
A key strength of our investigation is the use of longitudinal data with two 
measurements of HRV assessed over a decade in a non-clinical setting. Repeated measures of 
short-term HRV allow to attribute HRV to parasympathetic or/and sympathetic modulation 
and generally to cardiac autonomic status. Limitations include that the GHQ depression scale 
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used is only a part of the seven item depression scale of the 28-item GHQ. GHQ depression is 
also best considered to be a measure of depressive symptoms, and should not be equated with 
clinically diagnosed depression (Stansfeld et al. 1995). It is essentially a measure of self-
reported depressive symptoms and although reliable, it does not indicate the severity of 
depression. There is also the issue that we measured depressive symptoms at a single point in 
time 10 years after the original assessment. Since depression is episodic, it could be that we 
have not picked up depressive problems that occurred at other times during this period.  We 
also cannot rule out the contribution of device effects as different recording equipment was 
used to measure HRV at each phase. However the HRV protocols were consistent across all 
data collection phases. We also did not use any autonomic provocative maneuver which may 
limit the HRV data comparisons. Finally, the Whitehall II study is an occupational-based 
cohort, and is therefore healthier on average than the general population. However, etiological 
findings from the Whitehall II cohort have been shown to be comparable to other population-
based studies (Batty et al. 2014).  
In summary, our findings suggest that low HRV and vagal modulation may underlie 
deficits in self-regulation in those with depression and may be implicated in the generation of 
depressive episodes. Improvement in cardiac vagal modulation has potentially important 
future applications on the treatment of depression.   
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Table 1 Correlates of HRV and depressive symptoms at phase 5 (1997–1999) and 9 (2007–
2009) by sex 
 Phase 5 (1997-1999) Phase 9 (2007-2009) 
 Men Women Men Women 
n 2,268 949 3,451 1,293 
GHQ depressive symptoms score, mean (SD) 
GHQ depression caseness (GHQ ≥ 4), n (%) 
Heart rate b/min (SE) 
SDNN ms (SE) a 
LF-HRV ms2 (SE) a 
HF-HRV ms2 (SE) a 
RMSSD ms (SE) a 
1.00 (1.8) 
283 (12.5) 
68.89 (0.22) 
34.06 (1.01) 
319.68 (1.02) 
115.29 (1.02) 
19.56 (1.01) 
1.25 (2.0) 
145 (15.3) 
70.81 (0.34) 
32.54 (1.01) 
243.98 (1.03) 
140.21 (1.04) 
20.91 (1.02) 
0.66 (1.45) 
270 (7.5) 
66.72 (0.19) 
30.34 (1.01) 
234.75 (1.02) 
86.42 (1.03) 
18.34 (1.01) 
0.89 (1.71) 
133 (9.8) 
68.72 (0.31) 
29.56 (1.01) 
197.29 (1.03) 
106.25 (1.03) 
19.27 (1.02) 
Age, y, mean (SD) 
White ethnic origin, n (%) 
Low employment grade, n (%) 
55.7 (6.1) 
2,137 (94.0) 
86 (7.9) 
56.5 (6.1) 
813 (85.6) 
166 (37.4) 
65.4 (5.8) 
3,366 (93.8) 
179 (7.2) 
65.2 (5.7) 
1,161 (85.8) 
342 (33.5) 
Current smoker, n (%) 
Little or none physical activity, n (%) 
High alcohol intake, n (%) 
 200 (8.8) 
1,633 (72.2) 
687 (30.2) 
110 (11.7) 
783 (83.3) 
171 (18.0) 
194 (5.6) 
2,478 (69.2) 
734 (20.5) 
58 (4.5) 
1,038 (76.9) 
225 (16.6) 
Cardio-metabolic condition, n (%)b 971 (42.7) 430 (45.3) 1666 (56.7) 672 (60.3) 
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Prescribed medication use, n (%) 
Antidepressant medication, n (%) 
842 (37.1) 
44 (1.9) 
 530 (55.9) 
37 (3.9) 
2,776 (77.4) 
116 (3.2) 
1,124 (83.0) 
86 (6.4) 
aAge-adjusted geometric-mean and standard error 
bPresence of any of the following cardio-metabolic conditions: diagnosed coronary heart 
disease, heart failure, stroke, diabetes, hypertension and/or  obesity  
Abbreviations: HF-HRV = high frequency heart rate variability; LF-HRV = low frequency 
heart rate variability; RMSSD = root mean square of successive differences of normal-to-
normal RR intervals; SDNN = standard deviation of all intervals between R waves with 
normal-to-normal conduction 
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Table 2 Cross-sectional relationship of heart rate and HRV measures with depressive 
symptoms at phase 5 (1997–1999) and phase 9 (2007–2009) in individuals without 
antidepressant use 
  Baseline (Phase 5)    Follow-up (Phase 9)  
 n β (CI) p  n β (CI) p 
Heart rate        
 Men 2224 0.01 (-0.27 to 0.26) 0.97  3335 0.18 (-0.11 to 0.47) 0.22 
 Women 912 0.03 (-0.31 to 0.37) 0.86  1207 0.00 (-0.36 to 0.36) 0.99 
SDNN        
 Men 2224 -0.01 (-0.02 to 0.01) 0.26  3335 -0.01 (-0.03 to -0.001) 0.04 
 Women 912 -0.01 (-0.02 to 0.01) 0.48  1207 -0.003 (-0.02 to 0.01) 0.70 
LF-HRV        
 Men 2224 -0.02 (-0.04 to 0.01) 0.20  3335 -0.03 (-0.06 to -0.01) 0.02 
 Women 912 -0.01 (-0.04 to 0.03) 0.77  1207 -0.02 (-0.05 to 0.02) 0.42 
HF-HRV        
 Men 2224 -0.02 (-0.04 to 0.01) 0.24  3335 -0.04 (-0.07 to -0.001) 0.04 
 Women 912 0.001 (-0.04 to 0.04) 0.96  1207 -0.01 (-0.05 to 0.03) 0.73 
RMSSD        
 Men 2224 -0.002 (-0.02 to 0.01) 0.82  3335 -0.01 (-0.03 to 0.01) 0.14 
 Women 912 -0.002 (-0.02 to 0.02) 0.83  1207 -0.01 (-0.03 to 0.02) 0.67 
Abbreviations: CI = confidence interval; HF-HRV = high frequency heart rate variability; LF-
HRV = low frequency heart rate variability; RMSSD = root mean square of successive 
differences of normal-to-normal RR intervals; SDNN = standard deviation of all intervals 
between R waves with normal-to-normal conduction 
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Table 3 Prospective association between heart rate and HRV measures at phase 5 (1997-
1999) and depressive symptoms at phase 9 (2007-2009) 
aparticipants without depressive episode at phase 4 and 5 (GHQ ≥ 4 or use of antidepressant 
medication) 
bOR adjusted for age, ethnicity and depressive symptoms score at phase 5 
Abbreviations: CI = confidence interval; HF-HRV = high frequency heart rate variability; LF-
HRV = low frequency heart rate variability; RMSSD = root mean square of successive 
differences of normal-to-normal RR intervals; SDNN = standard deviation of all intervals 
between R waves with normal-to-normal conduction 
  
 
na ORb 95% CI p  
Heart rate      
 Men 1690 1.02 1.01 – 1.04 0.011  
 Women 644 1.03 1.00 – 1.05 0.062  
SDNN      
 Men 1690 0.57 0.36 – 0.89 0.013  
 Women 644 0.62 0.33 – 1.18 0.147  
LF-HRV      
 Men 1690 0.77 0.63 – 0.94 0.010  
 Women 644 0.80 0.59 – 1.08 0.143  
HF-HRV      
 Men 1690 0.81 0.67 – 0.98 0.031  
 Women 644 0.90 0.70 – 1.16 0.424  
RMSSD      
 Men 1690 0.65 0.46 – 0.92 0.016  
 Women 644 0.76 0.48 – 1.21 0.255  
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Table 4 Adjusted prospective association between heart rate and HRV at phase 5 (1997-1999) and  depressive symptoms at phase 9a (2007-2009) 
in men 
 amen without depressive episode at phase 4 and 5 (GHQ ≥  4 or use of antidepressant medication) 
Abbreviations: CI = confidence interval; HF-HRV = high frequency heart rate variability; LF-HRV = low frequency heart rate variability; SDNN 
= standard deviation of all intervals between R waves with normal-to-normal conduction; RMSSD =  root mean square of successive differences 
of normal-to-normal RR intervals  
Model 1 (n =1690): analysis adjusted for age, ethnicity and cognitive symptoms of depression score at phase 5 ; model 2 (n= 1684): model 1 + 
socioeconomic status; model 3 (n= 1676): model 1 + smoking, physical inactivity, high alcohol intake; model 4 (n = 1690): model 1 + cardio-
metabolic condition (diagnosed coronary heart disease, heart failure, stroke, diabetes, hypertension and obesity); model 5 (n = 1690): model 1 + 
prescribed medication use;  model 6 (n = 1670): all covariates. 
 
Model 1 
OR (95% CI) 
p Model 2 
OR (95% CI) 
p Model 3 
OR (95% CI) 
p Model 4 
OR (95% CI) 
p Model 5 
OR (95% CI) 
p Model 6 
OR (95% CI) 
p 
Heart rate 1.02 (1.0-1.04) 0.01 1.02 (1.01-1.04) 0.01 1.02 (1.01-1.04) 0.02 1.02 (1.01-1.04) 0.01 1.02 (1.01-1.04) 0.01 1.02 (1.01-1.04) 0.02 
SDNN 0.57 (0.36–.89) 0.01 0.57 (0.36–0.87) 0.01 0.60(0.37–0.95) 0.03 0.57 (0.36–0.89) 0.01 0.58 (0.37–0.91) 0.02 0.60 (0.37–0.96) 0.03 
LF-HRV 0.77 (0.63-0.94) 0.01 0.77 (0.63-0.94) 0.01 0.78 (0.64-0.96) 0.02 0.77 (0.63-0.94) 0.01 0.78 (0.63-0.95) 0.01 0.78 (0.63-0.97) 0.02 
HF-HRV 0.81 (0.67-0.98) 0.03 0.81 (0.67-0.98) 0.04 0.83 (0.68-1.00) 0.05 0.81 (0.67-0.98) 0.03 0.82 (0.68-0.99) 0.04 0.83 (0.68-1.00) 0.05 
RMSSD 0.65 (0.46-0.92) 0.02 0.65 (0.46-0.93) 0.02 0.68 (0.48-0.96) 0.03 0.65 (0.46-0.92) 0.02 0.66 (0.47-0.93) 0.02 0.68 (0.48-0.95) 0.03 
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Figure title and legend 
 
Figure 1. Baseline Heart rate and HRV (1997-1999) and risk of incidence depressive 
symptoms 10 years later (2007-2009) in men and women without depressive episode at 
baseline. The figure shows that higher levels of heart rate and HRV measures are associated 
with higher and lower risk, respectively, of incidence depressive symptoms.  
 
bOR adjusted for age, ethnicity and depressive symptoms score at phase 5 
Abbreviations: HF-HRV = high frequency heart rate variability; LF-HRV = low frequency 
heart rate variability; RMSSD = root mean square of successive differences of normal-to-
normal RR intervals; SDNN = standard deviation of all intervals between R waves with 
normal-to-normal conduction 
  
